Prot #CA-4948-102: A Phase 1/2a, Open-label Dose Escalation and Cohort Expansion Study of Orally Administered ca-4948 (IRAK4I) as a Monotherapy in Patients with Acute Myelogenous Leukemia or Myelodysplastic Syndrome and in Combination with Azacitidine or

Project: Research project

Project Details

StatusActive
Effective start/end date3/7/233/7/26

Funding

  • Catalyst Clinical Research, LLC (Prot #CA-4948-102 // Prot #CA-4948-102)
  • Curis, Inc. (Prot #CA-4948-102 // Prot #CA-4948-102)